MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Inflammatory Bowel Disease
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

6,452 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
6,452 works in the cohort · of 4,299,418page 79 of 130

Labels cover 21 of 6,452 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 6,452 of 6,452 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affunlabeled
P593 Efficacy of Risankizumab in Patients With Moderately to Severely Active Ulcerative Colitis by Prior Advanced Therapy Failure and Mechanism of Action: Post Hoc Analysis of the INSPIRE and COMMAND Phase 3 Studies
Remo Panaccione, Édouard Louis, Jean‐Frédéric Colombel, Geert D’Haens, Laurent Peyrin‐Biroulet, M Dubinsky +12 more
2024· article· en· Journal of Crohn s and Colitis· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
2
citations
affunlabeled
S1240 The Efficacy of Maintenance Treatment with Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results at Week 44 by Biologic/Janus Kinase History
Jessica R. Allegretti, Julián Panés, Laurent Peyrin-Biroulet, Bruce E. Sands, Shadi Yarandi, Kuan‐Hsiang Gary Huang +10 more
2024· article· en· The American Journal of Gastroenterology· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
2
citations
affunlabeled
S1193 Safety of Upadacitinib in IBD: Pooled Analysis of Phase 3 Maintenance Studies, U-ACHIEVE and U-ENDURE, In Patients With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease
Remo Panaccione, Julián Panés, Laurent Peyrin‐Biroulet, Jean‐Frédéric Colombel, James O. Lindsay, Filip Baert +10 more
2023· article· en· The American Journal of Gastroenterology· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
2
citations
affaboutunlabeled
Vedolizumab for the treatment of ulcerative colitis
Neal Shahidi, Brian Bressler, Remo Panaccione
2015· review· en· Expert Opinion on Biological Therapy· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
2
citations
affno abstractunlabeled
Nonbiologic Immune Suppression in Ulcerative Colitis
Valérie Heron, Edward V. Loftus
2020· review· en· Gastroenterology Clinics of North America· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
2
citations

How this was built: Screen · Findings · About